PFBT
ELVN icon

Parkside Financial Bank & Trust’s Enliven Therapeutics ELVN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$762 Hold
15
– – ﹤0.01% 2498
2026
Q1 		$588 Buy
+15
New +$416 ﹤0.01% 2528
2025
Q4 		– Sell
-25
Closed -$512 – 2718
2025
Q3 		$512 Hold
25
– – ﹤0.01% 2565
2025
Q2 		$502 Buy
+25
New +$473 ﹤0.01% 2552

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Parkside Financial Bank & Trust's ELVN Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 15 shares worth $762. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Parkside Financial Bank & Trust first reported a position in ELVN in Q2 2025 and has held it in 4 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Parkside Financial Bank & Trust held 15 shares of Enliven Therapeutics worth $762 as of Q2 2026.
  • Parkside Financial Bank & Trust left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2498 holding.
  • Parkside Financial Bank & Trust first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.